
What is claimed is:


1. Use of Compound 3 of the formula:



3,

or an enantiomer, mixture of enantiomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating non-Hodgkin lymphoma (NHL), wherein the NHL is follicular lymphoma (FL), mantle cell lymphoma (MCL), or primary central nervous system lymphoma (PCNSL).


2. Use of Compound 1 of the formula:



1,

or a tautomer, isotopolog, or pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating non-Hodgkin lymphoma (NHL), wherein the NHL is follicular lymphoma (FL), mantle cell lymphoma (MCL), or primary central nervous system lymphoma (PCNSL).


3. The use of claim 2, wherein Compound 1 of the formula:



1,

is used in the manufacture of the medicament.


4. The use of claim 2, wherein a pharmaceutically acceptable salt of Compound 1 of the formula:



1,

is used in the manufacture of the medicament.

5. Use of Compound 2 of the formula:



2,

or a tautomer, isotopolog, or pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating non-Hodgkin lymphoma (NHL), wherein the NHL is follicular lymphoma (FL), mantle cell lymphoma (MCL), or primary central nervous system lymphoma (PCNSL).

6. The use of any one of claims 1 to 5, wherein the NHL is follicular lymphoma (FL).

7. The use of any one of claims 1 to 5, wherein the NHL is mantle cell lymphoma (MCL).

8. The use of any one of claims 1 to 5, wherein the NHL is primary central nervous system lymphoma (PCNSL).

9. The use of any one of claims 1 to 8, wherein the NHL is relapsed or refractory NHL.

10. The use of claim 9, wherein the NHL is relapsed or refractory follicular lymphoma.

11. The use of claim 9, wherein the NHL is relapsed or refractory mantle cell lymphoma.


12. The use of claim 9, wherein the NHL is relapsed or refractory primary central nervous system lymphoma.

13. The use of any one of claims 9 to 12, wherein the subject has failed at least one prior

therapy.

14. The use of any one of claims 1 to 8, wherein the NHL is newly diagnosed.


15. Use of Compound 3 of the formula:



3,

or an enantiomer, mixture of enantiomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in a subject, wherein the subject has been treated with two or more prior lines of treatment.


16. Use of Compound 1 of the formula:



1,

or a tautomer, isotopolog, or pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in a subject, wherein the subject has been treated with two or more prior lines of treatment.

17. The use of claim 16, wherein Compound 1 of the formula:




1,

is used in the manufacture of the medicament.

18. The use of claim 16, wherein a pharmaceutically acceptable salt of Compound 1 of the


formula:



1,

is used in the manufacture of the medicament.

19. Use of Compound 2 of the formula:



2,

or a tautomer, isotopolog, or pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in a subject, wherein the subject has been treated with two or more prior lines of treatment.

20. The use of any one of claims 15 to 19, wherein the DLBCL is refractory to doxorubicin.

21. The use of any one of claims 1 to 20, wherein the medicament is manufactured to be administered orally.

22. The use of any one of claims 1 to 21, wherein the medicament is manufactured to be administered once daily for 5 days followed by 2 days of rest.

23. The use of any one of claims 1 to 21, wherein the medicament is manufactured to be administered once daily for 5 days followed by 9 days of rest.

24. The use of any one of claims 1 to 21, wherein the medicament is manufactured to be administered once daily for 7 days followed by 7 days of rest.

25. The use of any one of claims 1 to 21, wherein the medicament is manufactured to be administered once daily for 10 days followed by 4 days of rest.

26. The use of any one of claims 1 to 21, wherein the medicament is manufactured to be administered once daily for 14 days followed by 14 days of rest.

27. The use of any one of claims 1 to 21, wherein the medicament is manufactured to be administered once daily for 21 days followed by 7 days of rest.

28. The use of any one of claims 1 to 21, wherein the medicament is manufactured to be administered on days 1 to 5 of a 7-day cycle, on days 1 to 5 of a 14-day cycle, on days 1 to 7 of a 14-day cycle, on days 1 to 10 of a 14-day cycle, on days 1 to 14 of a 28-day cycle, on days 1 to 21 of a 28-day cycle, on days 1 to 5, days 8 to 12, days 15 to 19, and days 22 to 26 of a 28-day cycle, on days 1 to 5 and days 15 to 19 of a 28-day cycle, on days 1 to 7 and days 15 to 21 of a 28-day cycle, or on days 1 to 10 and days 15 to 24 of a 28-day cycle.

29. The use of any one of claims 1 to 28, wherein the medicament is manufactured for the compound to be administered in an amount of about 0.1 mg, about 0.2 mg, about 0.4 mg, about 0.6 mg, about 0.8 mg, about 1.2 mg or about 1.6 mg per day.

30. The use of any one of claims 1 to 29, wherein the medicament is manufactured to be administered in combination with rituximab.

31. The use of claim 30, wherein rituximab is to be administered intravenously.

32. The use of claim 31, wherein rituximab is to be administered at a dose of about 375 mg/m^2.

33. The use of any one of claims 30 to 32, wherein rituximab is to be administered once every 7 days, once every 4 weeks, or once every 8 weeks.

34. The use of any one of claims 30 to 32, wherein (i) rituximab is to be administered on days 1, 8, 15, and 22 of the first 28-day cycle (“Cycle 1”), on day 1 of the second to the sixth 28-day cycles, and then once every 8 weeks; and (ii) the medicament is manufactured for Compound 1 or a pharmaceutically acceptable salt thereof to be administered in cycles of once daily for 5 days followed by 2 days of rest, starting on day 1 of Cycle 1.

35. The use of any one of claims 30 to 32, wherein (i) rituximab is to be administered on

days 1, 8, 15, and 22 of the first 28-day cycle (“Cycle 1”), on day 1 of the second to the sixth 28-day cycles, and then once every 8 weeks; and (ii) the medicament is manufactured for Compound 1 or a pharmaceutically acceptable salt thereof to be administered in cycles of once daily for 5 days followed by 9 days of rest, starting on day 1 of Cycle 1.

36. The use of any one of claims 30 to 32, wherein (i) rituximab is to be administered on days 1, 8, 15, and 22 of the first 28-day cycle (“Cycle 1”), on day 1 of the second to the sixth 28-day cycles, and then once every 8 weeks; and (ii) the medicament is manufactured for Compound 1 or a pharmaceutically acceptable salt thereof to be administered in cycles of once daily for 7 days followed by 7 days of rest, starting on day 1 of Cycle 1.

37. The use of any one of claims 30 to 32, wherein (i) rituximab is to be administered on days 1, 8, 15, and 22 of the first 28-day cycle (“Cycle 1”), on day 1 of the second to the sixth 28-day cycles, and then once every 8 weeks; and (ii) the medicament is manufactured for Compound 1 or a pharmaceutically acceptable salt thereof to be administered in cycles of once daily for 10 days followed by 4 days of rest, starting on day 1 of Cycle 1.

38. The use of any one of claims 30 to 32, wherein (i) rituximab is to be administered on days 1, 8, 15, and 22 of the first 28-day cycle (“Cycle 1”), on day 1 of the second to the sixth 28-day cycles, and then once every 8 weeks; and (ii) the medicament is manufactured for Compound 1 or a pharmaceutically acceptable salt thereof to be administered in cycles of once daily for 14 days followed by 14 days of rest, starting on day 1 of Cycle 1.

39. The use of any one of claims 30 to 32, wherein (i) rituximab is to be administered on days 1, 8, 15, and 22 of the first 28-day cycle (“Cycle 1”), on day 1 of the second to the sixth 28-day cycles, and then once every 8 weeks; and (ii) the medicament is manufactured for Compound 1 or a pharmaceutically acceptable salt thereof to be administered in cycles of once daily for 21 days followed by 7 days of rest, starting on day 1 of Cycle 1.